R(-)-Methylenedioxymetamfetamine - Mindmed
Alternative Names: MM-402; R(-)-3,4-Methylenedioxymethamphetamine; R(-)-MDMA; R(-)-MethylenedioxymetamfetamineLatest Information Update: 12 Nov 2024
Price :
$50 *
At a glance
- Originator The University Hospital of Basel
- Developer Mindmed
- Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pervasive child development disorders
Most Recent Events
- 31 Oct 2024 Mindmed completes a phase I clinical trials in Pervasive child development disorders (In volunteers)
- 13 Jan 2024 University Hospital Basel completes a phase I trial for Pervasive child development disorders (In volunteers) in Switzerland (NCT05277636)
- 01 Oct 2023 Phase-I clinical trials in Pervasive child development disorders (In volunteers) (unspecified route)